logo-loader
viewGenedrive PLC

Genedrive moves to cash position as bondholder converts loan

Following completion, Genedrive will have gross cash balances of £8.6mln and debt of £2.6mln

Genedrive PLC -

Genedrive PLC (LON:GDR), the diagnostics group, has moved into a cash surplus after the Global Health Investment Fund (GHIF) converted its US$8mln bond into new shares.

At present, the bond and accrued interest are valued at US$9.46mln.

GHIF will be allotted 7.1mln new shares and £685,000 in cash to reflect the balance of accrued interest. 

Following completion, Genedrive will have gross cash balances of £8.6mln and debt of £2.6mln.  

A lock-up arrangement means 5.1mln of the GHIF shares are subject to an orderly marketing agreement until June 30, 2021, and the remaining 2mln cannot be sold before then.

Genedrive’s market value has rocketed in recent months as it has unveiled two diagnostic tests for coronavirus (COVID-19).

The company’s SARS -CoV2 kit was awarded a CE mark in May and is predicted by brokers to generate revenues of up to £1.5mln per week when sales start this month.

A second test for use outside of hospitals is also under development.

Shares eased 10% to 101p. In March, they were trading hands at 9p.

Quick facts: Genedrive PLC

Price: 73.5 GBX

AIM:GDR
Market: AIM
Market Cap: £38.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genedrive's David Budd details launch of its unique coronavirus test kits...

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version...

on 29/5/20

2 min read